Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CKD-350 (Xenobella) in Dry Eye Syndrome
NCT02777723Phase 3Unknown
- Sponsor
- Chong Kun Dang Holdings
- Start
- May 2016
- Primary completion
- Jul 2016
- Modality
- Polymer-based Nanoparticles
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of Xenobella in dry eye syndrome (DED) (2 arms), sponsored by Chong Kun Dang Holdings. Primary endpoint: Changes in Corneal Staining by Oxford scale at 4 weeks. Status: unknown.
02
Drugs
Xenobella
03
Conditions
dry eye syndrome (DED)
Beyond the preview
Go deeper on NCT02777723.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02777723.